ArticleDiagnostics (Basel, Switzerland)2026
Delayed Imaging Response After Chemoradiotherapy in a Patient with Unresectable Brainstem Pilocytic Astrocytoma.
Article in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult brainstem gliomas (BSGs) are rare malignant tumors of the central nervous system (CNS) that are difficult to resect completely via surgery, so chemoradiotherapy (CRT) is the primary treatment modality. However, there is substantial interpatient variability in therapeutic response to CRT among patients with BSGs. Here we present a case of a 41-year-old man who had experienced right limb weakness for 3 months. Brain MRI showed a solid-cystic mass in the brainstem, involving the medulla oblongata and the cervical spinal cord. The pathological diagnosis was pilocytic astrocytoma, CNS WHO Grade 1. Since the solid-cystic mass in the brainstem was unresectable, the patient received concurrent CRT followed by temozolomide (TMZ) maintenance chemotherapy. No significant change in tumor size was observed after concurrent CRT. Notably, 15 months after radiotherapy (19 months since the initial diagnosis), the tumor size decreased significantly. Up to the latest follow-up, the patient has maintained sustained partial remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.